Stockscreener 앱 받기
35.50
0.48%
0.06
전일 마감가:
$35.44
열려 있는:
$35.88
하루 거래량:
315.61K
Relative Volume:
0.29
시가총액:
$4.15B
수익:
$22.57M
순이익/손실:
$-212.73M
주가수익비율:
-19.67
EPS:
-1.8045
순현금흐름:
$-142.19M
1주 성능:
+5.60%
1개월 성능:
+19.81%
6개월 성능:
-14.09%
1년 성능:
+102.21%
1일 변동 폭
$35.00
$36.20
1주일 범위
$34.00
$36.73
52주 변동 폭
$16.79
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
35.49 | 4.14B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
436.96 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.07 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.41 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.00 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.91 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Technical Reactions to NAMS Trends in Macro Strategies - Stock Traders Daily
NewAmsterdam Pharma Co NV (HAM:KH6) Cyclically Adjusted Pri - GuruFocus
Bain Life Sciences trims NewAmsterdam (NAMS) holding to about 3.3% - Stock Titan
Trading the Move, Not the Narrative: (NAMS) Edition - Stock Traders Daily
NewAmsterdam Pharma Company N.V.Ordinary Shares (NQ: NAMS - FinancialContent
Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts - Sahm
NewAmsterdam Pharma Company N.V. (NAMS) Eps Diluted (TTM) - Zacks Investment Research
NAMS: Interim PREVAIL results expected Q1 next year, with strong efficacy and broad market potential - TradingView
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight By Investing.com - Investing.com Nigeria
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight - Investing.com
HC Wainwright Has Negative Forecast for NAMS Q2 Earnings - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 42.02 USD By Investing.com - Investing.com India
TradingKey - TradingKey
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL TrialSlideshow (NASDAQ:NAMS) 2026-05-11 - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones - simplywall.st
NewAmsterdam Pharma stock hits all-time high at 42.02 USD - Investing.com
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May - GlobeNewswire
Number of shareholders of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NewAmsterdam Pharma Company NV (NAMS) reports Q1 loss, tops revenue estimates - MSN
NewAmsterdam Pharma Hits Day High with 12.46% Surge in Stock Price - Markets Mojo
NewAmsterdam Pharma (NAMS) Deep Quarterly Loss Tests Bullish Growth And Valuation Narratives - Sahm
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam says its 9,500-patient heart trial gets an interim look in 4Q26 - Stock Titan
Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses? - Yahoo Finance
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends - Yahoo Finance
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom - ChartMill
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q1 Revenue $3.0M, vs. FactSet Est of $1.1M - marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q1 Revenue $3.0M, Vs. FactSet Est of $1.1M - Moomoo
NewAmsterdam Pharma (NAMS) posts Q1 2026 loss with $707M cash and key trial milestones - Stock Titan
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - marketscreener.com
NewAmsterdam Pharma (NASDAQ: NAMS) reports $48M Q1 2026 loss - Stock Titan
Number of shareholders of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
All eyes on NewAmsterdam Pharma earnings as pipeline advances By Investing.com - Investing.com Nigeria
All eyes on NewAmsterdam Pharma earnings as pipeline advances - Investing.com
FMR LLC boosts disclosure: PHARMA COMPANY NV (NAMS) 8.77M shares reported - Stock Titan
[ARS] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma (NAMS) outlines 2026 AGM votes, ESPP and share issuance powers - Stock Titan
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Five new hires at NewAmsterdam get stock awards covering 65,800 shares - Stock Titan
Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Jennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
What sustainable investing NewAmsterdam (NAMSW)? (+5.61%) 2026-04-29Community Watchlist - Newser
143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLC - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8%What's Next? - MarketBeat
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):